Teva reports $500M duvakitug milestone, $2.2B debt issuance, and $29.6B goodwill impairment

TEVA PHARMACEUTICAL INDUSTRIES LTD

$500M milestone received in Q4 2025 for duvakitug Phase 3 initiation; $500M upfront in Q4 2023.
Issued $700M 5.75% notes due 2030, €1B 4.125% due 2031, $500M 6.00% due 2032 in May 2025.
Tender offer extinguished $1.579B of 3.15% notes due 2026 and other notes; $10M loss recorded.
Cumulative goodwill impairment stable at $29.6B as of Dec 31, 2025 and 2024.
Repaid $1.812B of senior notes maturing in 2025 during the year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.